Leukotriene receptor antagonist drugs for asthma

Medical Journal of Australia

Volumn 171, Issue 7, 1999, Pages 378-381

  Thien, Francis C K ^a,b  

^a MONASH UNIVERSITY MEDICAL SCHOOL   (Australia)

^b ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; LEUKOTRIENE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; PEPTIDOLEUKOTRIENE; STEROID; ZAFIRLUKAST;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHMA; BRONCHODILATATION; CHURG STRAUSS SYNDROME; DIARRHEA; DOSE TIME EFFECT RELATION; EXERCISE; HEADACHE; HUMAN; INFLAMMATION; INHALATIONAL DRUG ADMINISTRATION; LIVER DYSFUNCTION; LUNG FUNCTION; NAUSEA; ORAL DRUG ADMINISTRATION; SYMPTOM;

EID: 0033523675     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: 10.5694/j.1326-5377.1999.tb123698.x     Document Type: Article

References (23)

1. Thien FCK, Walters EH. Eicosanoids and asthma: an update. Prost Leuk Essent Fatty Acids 1995; 52: 271-288.
2. Taylor GW, Taylor IK, Black P, et al. Urinary leukotriene E4 after antigen challenge and in acute asthma and allergic rhinitis. Lancet 1989; 1: 584-588.
3. Wenzel SE, Wastcott JY, Larsen GL. Bronchoalveolar lavage fluid mediator levels 5 minutes after allergen challenges in atopic subjects with asthma: relationship to the development of late asthmatic responses. J Allergy Clin Immunol 1991; 87: 540-548.
4. Drazen JM. Comparative contractile responses to sulfidopeptide leukotrienes in normal and asthmatic human subjects. Ann N Y Acad Sci 1988; 524: 289-297.
5. Krell RD, Aharony D, Buckner CK, et al. The preclinical pharmacology of ICI 204,219, a peptide leukotriene antagonist. Am Rev Respir Dis 1990; 141: 978-987.
6. Lynch KR, O'Neill GP, Liu Q, et al. Characterization of the human cysteinyl CysLT, receptor. Nature 1999; 399: 789-793.
7. Taylor IK, O'Shaughnessy KM, Fuller RW, Dollery CT. Effect of cysteinyl-leukotriene receptor antagonist ICI 204,219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects. Lancet 1991; 337: 690-693.
8. National Health and Medical Research Council. A guide to the development, implementation and evaluation of clinical practice guidelines. Canberra: NHMRC, Aus-lnfo 1999.
9. Roquet A, Dahlen B, Kumlin M, et al. Combined antagonism of leukotrienes and histamine produces predominant inhibition of allergen-induced early and late phase airway obstruction in asthmatics. Am J Respir Crit Care Med 1997; 155: 1856-1863.
10. Calhoun WJ, Lavins BJ, Minkwitz MC, et al. Effect of zafirlukast (Accolate) on cellular mediators of inflammation: bronchoalveolar lavage fluid findings after segmental antigen challenge. Am J Respir Crit Care Med 1998; 157 (5 Pt 1): 1381-1389.
11. McFadden ER Jr, Gilbert IA. Exercise-induced asthma. N Engl J Med 1994; 330: 1362-1367.
12. Leff JA, Busse WW, Pearlman D, et al. Montelukast, a leukotriene-receptor antagonist for the treatment of mild asthma and exercise-induced bronchoconstriction. N Engl J Med 1998; 339: 147-152.
13. Christie PE, Smith CM, Lee TH. The potent and selective sulfidopeptide leukotriene antagonist, SK&F 104353, inhibits aspirin-induced asthma. Am Rev Respir Dis 1991; 144: 957-958.
14. Dahlen B, Margolskee DJ, Zetterstrom O, Dahlen SE. Effect of the leukotriene receptor antagonist MK-0679 on baseline pulmonary function in aspirin sensitive asthmatic subjects. Thorax 1993; 48: 1205-1210.
15. Spector SL, Smith LJ, Glass M. Accolate Asthma Trialists Group. Effect of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. Am J Respir Crit Care Med 1994; 150: 618-623.
16. Reiss TF, Chervinsky R Dockhorn RJ, et al. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group. Arch Intern Med 1998; 158: 1213-1220.
17. Kemp JR Minkwitz MC, Bonuccelli CM, Warren MS. Therapeutic effect of zafirlukast as monotherapy in steroid-naive patients with severe persistent asthma. Chest 1999; 115: 336-342.
18. Knorr B, Matz J, Bernstein JA, et al. Montelukast for chronic asthma in 6-to 14 year-old children - a randomized, double blind trial. JAMA 1998; 279: 1181-1186.
19. Hui KP, Barnes NC. Lung function improvement in asthma with a cysteinyl-leukotriene antagonist. Lancet 1991; 1: 1062-1063.
20. Tamaoki J, Kondo M, Sakai N, et al. Leukotriene antagonist prevents exacerbation of asthma during reduction of high-dose inhaled corticosteroid. Am J Respir Crit Care Med 1997; 155: 1235-1240.
21. Malmstrom K, Rodriguez-Gomez G, Guerra J, et al. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma - a randomized, controlled trial Ann Intern Med 1999; 130: 487-495.
22. Busse W, Nelson H, Wolfe J, et al. Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma. J Allergy Clin Immunol 1999; 103: 1075-1080.
23. Churg A, Churg J. Steroids and Churg-Strauss syndrome. Lancet 1999; 352: 32-33.